|
Director, Pharmacoeconomics and Outcomes Research UnitedHealth Group |
|
|
Department Chair, Department of Healthcare Management and Informatics Albany College of Pharmacy and Health Sciences |
|
|
CHAIR in HEALTH ECONOMICS (2 POSTS) University Of Aberdeen |
|
|
|
News
- What drives patient adherence and compliance?
- Has lack of innovation resulted in plunging margins for medical device industry?
- Economics for a Better World: Call for health economics session proposals
- How Payers View Pfizer’s Rheumatoid Arthritis Pill
- Peddling pills to those who don't really need them
- How's that incentive plan working for you?
- Real-Life Case Studies Show Immense Savings with Health Reimbursement Arrangements
- New partnership seeks to create personalized health plans
- Implications for ACOs of Variations in Spending Growth
- Looking at CER from the Managed Care Organization Perspective
- Looking at CER from the Pharmaceutical Industry Perspective
- Call for papers: JMCP Specialty Pharmacy Issue
- The importance of keeping up to date on drug codes
- New Report: 2012 Benchmarks in Patient Registry Use for Accountable Care
- Should drug co-payments be based on the value that a drug provides?
- How to run a walking meeting
- Rising cost of ‘specialty’ drugs prompts employers to limit their use
- What will dominate future pricing and reimbursement strategies?
- Is the US healthcare system mired in maximizing reimbursement to the exclusion of patient outcomes?
- Four decades of health economics through a bibliometric lens
- The Results are IN! 6th Survey on Observational Reseach Webinar, May 22, 11am ET
- Video Interview: Dr. Robert W. Dubois discusses the BGOV study on CER
- New app helps treat OCD symptoms
- Saying 'no' to beneficial care
- Big potential for 'vitual' pharma
- How can integrated teams can provide more reliable forecasts?
- In-house Market Research function under attack, but this could apply to HEOR too:
- Leading health economist Mark V. Pauly, Ph.D., earns prize
- Top 10 Pharma CEO Salaries of 2011
- HHS enlists Archimedes Model
- Are observational studies a "necessary tool"?
- Thinking of developing a website to share information with doctors? Don’t bother.
- 10 tips for a great health care research article
- America's cancer survival rate controversy
- Can new legislation solve America's drug shortage problem?
- Beyond Market Access for Economic Development: EU-Africa Relations in Transition
- Bill Gates: global health care ambassador
- Health Economist wins top prize for Medicaid/Medicare findings
- How do HOLs spend the majority of their time?
- Country Report China
- Baffled by how to promote your HEOR message on the internet?
- Spain - yet another Royal Decree to cut costs
- Expansion of PA Policies for Oncology Agents
- Addressing Reimbursement During Drug Development
- If patients choose hospitals because of social media, will your HEOR customers choose you?
- PODCAST - How Did Pfizer roll-out the iPad? Learn from their challenges and surprises.
- Ukraine: Introduction of Reference Pricing and tightened rules for buying Drugs
- NPC comments on Addenda/Appendices to AMCP’s Format for Formulary Submissions Version 3.0
- Are Medicare payments driving down physician prices?
- What is the return on investment for health economics evidence?
- Can we trust the results of observational studies about CER?
- Insights from the frontlines of the CER debate
- Will new FDA mission statement undermine public health?
- What kind of health insurance do health economists buy?
- Professors skeptical of new health care documentary
- Cleansing Chinese Publishing
- Patient-Centered Outcomes Research Trust Fund Fees Assessed on Health Plans
- The Working Group on Relative Effectiveness
- Bargains at Costco: toilet paper, wine, and health insurance?
- Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- New oncology app for mobile tablet devices
- IMS Health Expands Services in Pharma R&D
- PCORI to release final list of priorities today
- The ol' bait and switch
- Survey Says....
- The election results are in!
- Available for download...
- Are incentive payments related to health gains?
- e-Learning course: Health Economics Managed Care
- The Economics of New Health Technologies : Incentives, organization, and financing
- What might the future look like for healthcare reimbursement?
- Pricing and Reimbursement Strategies for Medical Devices
- Could Value-Based Pricing Transform Cost-Effectiveness Analyses?
- Kill the bugs, save the world!
- Go Vertical or Go Home: Using the Vertical Analog Scale to assess the EuroQuol PRO measure.
- JAMA Theme Issue: CER
- Medical device marketing in modern times
- Investment Opportunity: Pharma stocks
- Formulary Data: There's an app for that!
- Webinar: AMNOG - One Year On
- What are biopharma's concerns in achieving commercial success?
- How to succeed in the new stakeholder environment
- The power of games
- Do you know about payer segmentation in the pharma marketplace?
- Kantar Health names new director
- CER unlikey to influence FDA
- Your mother was right!
- HTA Around the World: Lessons Learned
- Four decades of health economics through a bibliometric lens
- AstraZeneca finds big opportunity is China pharma market
- Are you in the clouds?
- The results are in...
- Can an agreement be made for a new drug pricing benchmark?
- A novel idea: Pay physicians for a treatment cycle that promotes better care and reduced drug costs
- And the winner is...
- Will the government be able to judge individual doctors?
- Are you up to date on privacy recommendations on email-enabled patient surveys?
- Cigna expands ACO program
- Delayed 1 year: new ICD-10 deadline proposed for October 2014
- Are your electronic health records safe?
- Check out the new HOL report from Cutting Edge
- ERT Announces Acquisition by Genstar Capital
- View the International Profiles of 13 Health Care Systems
- Comparing the use of CER in drug coverage and pricing decisions
- Will we see CER informing US policy decisions?
- Can CRO relationships enhance focus and flexibility for pharma industry?
- AstraZeneca's downward spiral
- The ABC’s of the Health Care Law and Its Future
- Is aetna's latest premium rate hike "unreasonable"?
- What are the Best Drug Companies Of The Past 15 Years?
- The writing is on the wall for pharma companies
- Embracing decision-support tools will drive evidence-based medicine
- How do Supreme Court justice's worldviews differ on the fundamental questions of health policy?
- Is China's new pricing model damaging drug quality and product revenue?
- How would you define specialty pharmacy?
- Need an easy solution for complicated models? Linked sliders can help.
- Irish Health Service imposes freeze on new medicines
- What do pacemakers and washing machines have in common?
- OHE celebrates 50 years with new archival website
- Call for nominations: CER National Leadership Awards
- Pharmaceutical Technology Assessment: Perspectives From Payers
- What's getting expensive the fastest?
- Weill Cornell Medical College Establishes Center for Healthcare Informatics and Policy
- How will CER impact pharmaceutical innovation?
- Input needed for Addenda/Appendices to AMCP's Format for Formulary Submissions
- More patient-level data needed for patient-centered outcomes research
- Economics for the Market of Medicines in the UK
- Duking out the healthcare debate
- If the Supreme Court tosses the individual mandate, what else comes down with it?
- Do you know the difference between an ACO & a HIE? Thomson Reuters is here to help!
- NICE 'inspires' price cut for Pradaxa
- Quintiles to incorporate Archimedes Simulator
- New Report: Pharmaceutical Pricing Strategy
- Survey says: Cautious optimism for use of CER in decision-making
- What is the Economic Rationale for the Health Care Law’s Individual Mandate?
- 2012 Shaping up to be an eventful year for healthcare
- New quality standards on the way from NICE
- Is IPAB the latest Apple Product?
- How do healthcare providers use the results from patient satisfaction surveys?
- New Journal Launched: Journal of Euromed Pharmacy
- Video: The Canadian Healthcare Debate
- New Pharma online magazine
- Is the current pharma business model broken?
- Interested in Online Graduate Education for an M.S. in Applied HEOR?
- Report: Prospective Observational Studies to Assess Comparative Effectiveness
- What is the ISPOR Medication Adherence and Persistence Special Interest Group?
- Do you know how to search PubMed for evidence?
- Podcast: The quality of life endpoint– If the car doesn’t drive faster you don’t need a better seat!
- Podcast: Why clear benefit for the patient still comes top of the GBA checklist.
- Podcast: Prescriptions with a premium price – the good the bad and the ugly.
- Podcast: On the surface the German Market Access system appears centralised – is it really?
- Podcast: 'Value Based Pricing is going to completely change the roadmap...'
- Who's MABEL?
- National Health and Wellness Survey Expands into Russia
- Will the UK's NHS reform bill soon become law?
- AMCP comments on PCORI draft of National Priorities
- Lucrative Algorithms
- Arthur Caplan to Lead New Division of Medical Ethics
- How Does Medicaid Managed Care Affect Health Outcomes?
- Can "gamification" work for clinical research?
- How much is spent on health in America?
- Epic Fail: The staggering cost of inventing new drugs
- What swayed NICE to reverse draft guidance on new oral MS drug?
- Boston leads the way towards global payments
- Is "Bad Science" being used to justify UKs NHS shakeup?
- Will global pharma marketing continue to fall?
- New Pricing Strategy Report from Cutting Edge
- Novartis: Leading the way in emerging markets
- Will AMNOG cause Germany to find itself with one option per drug class?
- New paper: Get more, pay more?
- Using economic evaluations for drug reimbursement decisions - what have we achieved?
- How to control rising healthcare costs in China.
- PCORI finally nails down a definition
- What can data analytics bring to pharma's bottom line?
- NICE appoints new directors
- Farmeconomia accepting manuscripts
- ACO 101- A brief course by Neil Kirschner, Ph.D.
- Advancing the quality of electronic data collection
- Archived Webinar: New Online M.S. Program for Applied Health Economics & Outcomes Research
- Will revoking patent rights get Big Pharma in line?
- U.S. payers look to Europe
- ISPOR Performance-Based Risk-Sharing Arrangements Task Force
- Is HEOR the red headed step-child?
- The price of tea in China...oops...I mean drugs
- More growth for Big Pharma in China
- Video Interview: How does CER lead to better health decisions?
- New evidence-based medicine center at Brown
- What are the opportunities and challenges of the APAC region?
- New streamlined pricing and reimbursement proposal for Europe
- The Healthcare Communication Revolution
- ICON Selected by Roche for Technology Partnership
- How can phama adjust to meet evidence needs?
- Are health economists clueless bureaucrats?
- Read all about it! March 2012 PharmaVoice Magazine
- Abstracts from Professional Poster Presentations at AMCP’s 24th Annual Meeting & Expo
- Is the pharma industry seeing a "talent crunch"?
- The healthcare market in Japan
- ICON Acquires PriceSpective
- NICE denies "money-savings" accusations
- US Payers: Comparative Effectiveness Research and Formulary Decision-making
- Are innovative new drugs being held back to save governments money?
- European pharma debt write-off?
- New Russian Biofund partnership deal
- Do you know the four key metrics needed for a successful ACO pilot program?
- Grant Opportunity: Infrastructure Development Program in PCORI
- Call for Papers: Value in Health Regional Issues
- Most of us are lazy when it comes to choosing the best Journal in which to publish our HEOR data.
- Should health information websites be subject to peer review?
- Who has the cheapest drugs in EU?
- Delaware looking for "real-world evidence" to control Medicaid costs
- How can Big Pharma meet the "real world" data challenge?
- Will Germany's new pricing law drive Pharma away?
- Value-based pricing: a predatory opportunity?
- Austerity Pricing Limits in Europe as a Result of Financial Woes
- Will we soon see 'Brazil NICE' or 'China NICE'?
- Big Bad Pharma
- Practical Advice for Medical Device Firms
- Report: Pharmaceutical Licensing and Alliances in the Asia-Pacific Region
- What are PRO, ObsRO and ClinRO?
- Does the 2013 Obama budget threaten the pharmaceutical industry?
- What are the pros and cons of pharmacoeconmics research?
- Cost concerns dominate benefit design in 2012
- Will global health plans be offered by your insurer soon?
- UnitedHealth Group Launches Cloud Platform
- PCORI: Will $440 million be enough to make health care any more evidence-based?
- How can Pharma capture sales when their drugs go off patent?
- Why is Systematic Review essential for Pharma?
- What do you think of this? Alternative to Facebook for Pharma
- NICE not convinced of Botox's migraine value
- Statistical issues in comparative effectiveness research
- Do new ACP ethics guidelines imply patient care be more "stingy"?
- Patient Reported Outcomes success with eDiary in Clinical Trial
- Who would you like to nominate for the PharmaVOICE 100?
- What counterfeit drugs are on your doctors shelf?
- Research and Markets: 2012 Benchmarks in Patient Registry Use for Accountable Care
- ERT web traffic up 41%
- Is it time to appoint a 'Chief Patient Officer'?
- eyeforpharma Managed Care Summit 2012 Podcasts
- Has Johnson & Johnson lost its way?
- You can run but you can't hide
- Update from Patient-Centered Outcomes Research Institute
- Patient-Centered Outcomes Research: Evidence-Based System Transformation
- The Role of Government in CER
- WellPoint and Aetna launch new patient quality of care programs
- Is Obama budget short-sighted?
- How are differences in regulatory markets and payer demands affecting Phase IV Trials?
- How do scientists use social media?
- Road map for building Pharma 3.0
- Should you be concerned about value-driven health care?
- Will we see cheaper biosimilar drugs in the marketplace soon?
- Value is in the eye of the beholder
- Research teams from Express Scripts, HealthCore and WellPoint garner Excellence Awards
- What impact have reform and the recession had on U.S. healthcare costs?
- Who's to blame for destroying R&D value?
- Setting pay for performance targets
- How is AMNOG shaping up?
- Is Value Based Pricing the answer for the UK?
- Practical Advice for Medical Devices Firms
- What would happen to trends in health coverage and costs if health reforms are not enacted?
- Jumpstarting digital capabilities in pharma. How come it hasn't happened yet?
- How can value best be demonstrated to payers?
- Key Speakers added for DIA 2012: Collaborate to Innovate meeting
- Health outcomes liaisons in high demand
- Can Big Pharma cure cancer in emerging markets?
- Extending the Life Cycle of a Mature Brand in an Emerging Market
- Workforce Health and Productivity Report
- India's pharma success story
- What are the challenges working in the Asian-Pacific marketplace?
- Bayer's Cancer Cure?
- New market research on industry efforts to enhance the patient experience and satisfaction of care
- Should cost-effectiveness evidence be relevant in Medicare decision making?
- How to overcome mounting European pharma debt
- Will there be convergence between the UK's NICE and Germany's IQWiG?
- New Report Available - Market and Product Forecasts: Targeted Cancer Therapies
- How will German health reform impact pharma market access in 2012?
- Can competition help the integration of care?
- Trends in PRO: Interview with Dr. Arthur Stone
- The gamification of health care
- Proportion of Days Covered vs. Medication Possession Ratio
- Can you guess PharmExecs brand of the year?
- The three P’s of effectiveness research: PCORI, Priorities, and Politics
- How do price changes affect Medicare beneficiaries?
- Are patients' perspectives important from the beginning of clinical trials?
- Another prostate cancer pill bites the dust
- What's next for IBM's Watson?
- Integrating scientific and real-world evidence within and beyond the drug development process
- New Journal Launched - The Journal of Comparative Effectiveness Research
- NPC selects five research projects related to CER for funding in 2012
- "Big Brother" looms in FDA lawsuit
- Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?
- Gouge-fest. What do overpriced pharmaceuticals and textbooks have in common?
- Study participants needed to uncover strategies and tactics to improve patient adherence
- Does healthcare reform in France and Germany create market access barriers?
- How have NICE's HTA processes affected speed of access to new treatments?
- Different analytical approaches....different answers
- What are your thoughts about IBI's new Intervention Bank?
- Will you do this for your next medical education marketing message?
- How do you determine the economic benefits of vaccination in an increasing global world economy?
- Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
- What is the heart of a successful patient adherence program?
- Where to begin risk assessment? Begin at the end.
- Pharma and biotech boosting investment in medical affairs worldwide
- Embracing mobile health technology. Is our paradigm shifting?
- Germany's IQWiG sees added benefits for Incivo
- The Big Pharma Recession Report
- Nominations being sought for 7th Annual Strategic Patient Adherence Awards
- Institute of Clinical Research offers courses on medical device clinical trials and marketing.
- Why is pharma scared to innovate?
- PCORI Draft: National Priorities for Research and Research Agenda
- Public comments sought. What do you think about the PCORI National Priorities for Research draft?
- Is There a Role for Pharmacoeconomics in Developing Countries?
- Interesting flow chart summary of new FDA guidance
- ISPOR 5th Asia-Pacific Conference
- Video: Dr. Art Kaplan speaks on communication challenges for patients
- Patient Reported Outcomes. What can be gained from patient communication?
- Incremental Progress for Oncology in 2011
- The future of the Indian pharmaceutical market
- NICE’s Social Value Judgments about Equity in Health and Health Care
- CER Gaining Importance
- New descriptive analysis of more than 22,000 Cochrane meta-analyses
- Has the recession caused US citizens to forgo healthcare?
- Check out this suggested reading list for CER
- What's in it for ACO early adopters?
- Doctors on the take? Medical conflicts of interest.
- What is Encyclopedia: Patient-Reported Outcomes
- Modeling Health-Related Quality of Life over Time
- Research and Markets: Pharmacoeconomic Analysis in R&D Decision Making: An In-Depth Report
- Ethical and scientific questions surround HPV vaacinations
- Concerns surround New Outcomes Research Institute
- YouTube Video: Reimagining pharmaceutical innovation
- WP243 Thought Leader Compensation: US vs. EU
Featured Jobs
Conference Of The Week
Job Of The Week
Research Scientist - Health Economics
United BioSource Corp., Lexington, MA
Reserve "Job of the Week". Contact us.
Link Of The Week
Should drug co-payments be based on the value that a drug provides?
Some employers are changing co-pays to be based on value provided, particularly for pricier specialty drugs with no generic competition. What are the implications for your reimbursement plan and market share? (Source: NPR.org, 5/8/12)
Reserve "Link of the Week". Contact Us.
Survey Of The Week
Survey of the Week: Speak with 15,000+ professions in the health economics arena, and gather feedback, test a concept, or track trends.
Reserve "Survey of the Week". Contact us.


























